Session II of the Second International Colloquium on Cardio-Oncology, chaired by Dr Breccia (Rome, Italy) and Dr Jurczak (Krakòw, Poland), focused on mechanisms and clinical course of cardiovascular toxicity of cancer treatment. Whereas the venerable anthracyclines keep challenging patients and clinicians with risk of left ventricular dysfunction and heart failure, other newer drugs cause substantially different clinical phenotypes of cardiovascular toxicity. In particular, Session II not only focused on arterial thrombosis and venous thromboembolism, but also hypertension or cardiomyopathy or atrial fibrillation induced by many otherwise life-saving drugs. Dr Breccia (Rome, Italy) reviewed incidence, mechanisms, risk factors, and principles for prevention of cardiovascular events induced by tyrosine kinase inhibitors of hematologic interest, such as those used to treat chronic myeloid leukemia. Dr Carver (Philadelphia) reviewed the incidence, predisposing factors, and principles for proactive management of cardiovascular events in patients treated by conventional chemotherapy or new drugs for treatment of multiple myeloma. Dr Szmit (Warsaw, Poland) discussed on how coagulation disorders should be classified according to patient- or drug-related factors and how they should be diagnosed and treated in patients with solid or hematologic tumors. Dr Minotti (Rome. Italy) illustrated some potential pitfalls of accelerated drug development and approval and their possible impact on clinical incidence of cardiovascular events induced by tyrosine kinase inhibitors of hematologic interest. Session II therefore offered a broad perspective of the risk-benefit ratio of new drugs that are plagued with concerns about cardiovascular events.

中文翻译：

---

癌症治疗心血管毒性的机理和临床过程II。血液学☆。

在布雷西亚博士（意大利罗马）和尤尔恰克博士（波兰克拉科夫）的主持下，第二届国际心脏病学国际学术讨论会第二场会议重点讨论了癌症治疗心血管毒性的机制和临床过程。古老的蒽环类药物使具有挑战性的患者和临床医生面临左心室功能不全和心力衰竭的风险，而其他新药则导致心血管毒性的临床表型大相径庭。特别是，第二场会议不仅着眼于动脉血栓形成和静脉血栓栓塞，还着重讨论了许多其他可以挽救生命的药物引起的高血压或心肌病或房颤。Breccia博士（意大利罗马）回顾了对血液学感兴趣的酪氨酸激酶抑制剂诱发的心血管事件的发生率，机制，危险因素和预防原则，例如用于治疗慢性粒细胞白血病的药物。Carver博士（费城）回顾了通过常规化学疗法或治疗多发性骨髓瘤的新药治疗的心血管事件的发生率，诱发因素和积极处理心血管事件的原则。Szmit博士（波兰华沙）讨论了如何根据患者或药物相关因素对凝血障碍进行分类，以及在实体瘤或血液肿瘤患者中如何诊断和治疗凝血障碍。Minotti博士（意大利罗马）举例说明了加速药物开发和批准的一些潜在陷阱，以及它们可能对血液学方面的酪氨酸激酶抑制剂诱导的心血管事件的临床发生率产生影响。